May 4, 2020 / 11:24 AM / a month ago

Menarini Group to buy Stemline Therapeutics in deal valued at up to $677 mln

May 4 (Reuters) - Privately held Italian drugmaker Menarini Group on Monday agreed to buy U.S. company Stemline Therapeutics Inc in a deal valued at up to $677 million.

Stemline shareholders would get $12.50 per share, involving an upfront payment of $11.50 in cash, the companies said.

They will also get one non-tradeable contingent value right that entitles each shareholder to an additional $1 in cash per share upon completion of certain milestones, the companies said.

Stemline’s shares closed at $4.65 on Friday.

Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Nuestros Estándares:Los principios Thomson Reuters
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below